Stock listing
NASDAQ:ADGM Adagio Medical Holdings, Inc Stock
Home listing (NASDAQ) of Adagio Medical Holdings, Inc
Follow Adagio Medical Holdings, Inc into a list and get an email when it puts out news.
Share price · NASDAQ:ADGM
$1.75 USD +0.23 (+15.1%)
Close on Nov 20, 2026
- Day range
- $1.60 – $1.84 USDNov 20, 2026
- Volume
- 27,722 sharesNov 20, 2026
- Market cap
- $1.72M USDAt the close on Nov 20, 2026 · price × 983,434 shares outstanding
- 52-week range
- $0.081 – $2.32 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $371,032 USDMedian day 329,392 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:ADGM · Home | $1.75 USD | +0.23 (+15.1%) | 27,722 | $1.60 | $1.84 | $1.60 | $1.52 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:ADGM · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $1.75 | +0.23 | +15.1% | $1.60 | $1.84 | $1.60 | 27,722 | |
| $1.52 | -0.13 | -7.9% | $1.632 | $1.64 | $1.52 | 9,174 | |
| $1.65 | +0.04 | +2.5% | $1.54 | $1.65 | $1.45 | 13,696 | |
| $1.61 | -0.32 | -16.6% | $1.93 | $2.10 | $1.46 | 92,103 | |
| $1.93 | +0.11 | +6.0% | $1.82 | $1.964 | $1.82 | 36,045 | |
| $1.82 | -0.05 | -2.7% | $1.89 | $2.25 | $1.62 | 379,099 | |
| $1.87 | +0.03 | +1.6% | $1.84 | $1.87 | $1.61 | 52,494 | |
| $1.84 | -0.08 | -4.2% | $1.60 | $1.90 | $1.50 | 187,311 | |
| $1.92 | -0.03 | -1.5% | $2.19 | $2.32 | $1.80 | 1,103,137 | |
| $1.95 | +0.12 | +6.6% | $1.86 | $2.04 | $1.80 | 46,600 | |
| $1.83 | +1.744 | +2023.0% | $2.25 | $2.25 | $1.56 | 206,740 | |
| $0.086 | 0.00 | 0.0% | $0.09 | $0.09 | $0.085 | 155,850 | |
| $0.086 | -0.001 | -0.9% | $0.089 | $0.089 | $0.082 | 155,476 | |
| $0.087 | +0.004 | +4.8% | $0.092 | $0.093 | $0.085 | 276,954 | |
| $0.083 | -0.003 | -3.5% | $0.091 | $0.092 | $0.081 | 497,322 | |
| $0.086 | -0.02 | -18.9% | $0.108 | $0.115 | $0.083 | 1,178,820 | |
| $0.106 | +0.006 | +6.1% | $0.094 | $0.11 | $0.09 | 934,444 | |
| $0.10 | +0.003 | +3.4% | $0.098 | $0.108 | $0.095 | 299,584 | |
| $0.097 | -0.006 | -5.8% | $0.10 | $0.108 | $0.092 | 623,467 | |
| $0.103 | -0.008 | -7.4% | $0.108 | $0.11 | $0.101 | 712,624 | |
| $0.111 | -0.005 | -3.9% | $0.112 | $0.114 | $0.105 | 181,907 | |
| $0.115 | -0.006 | -4.6% | $0.118 | $0.122 | $0.108 | 768,738 | |
| $0.121 | +0.001 | +0.7% | $0.121 | $0.123 | $0.115 | 775,851 | |
| $0.12 | +0.021 | +21.2% | $0.101 | $0.124 | $0.096 | 3,109,302 | |
| $0.099 | -0.004 | -3.9% | $0.101 | $0.106 | $0.095 | 626,074 | |
| $0.103 | +0.014 | +15.7% | $0.088 | $0.106 | $0.084 | 25,148,547 | |
| $0.089 | -0.036 | -29.0% | $0.122 | $0.126 | $0.083 | 3,211,320 | |
| $0.125 | -0.007 | -5.1% | $0.13 | $0.136 | $0.121 | 793,854 | |
| $0.132 | +0.002 | +1.5% | $0.13 | $0.142 | $0.126 | 1,271,072 | |
| $0.13 | 0.00 | 0.0% | $0.126 | $0.13 | $0.126 | 690,432 | |
| $0.13 | -0.004 | -2.8% | $0.13 | $0.133 | $0.12 | 1,492,363 | |
| $0.134 | -0.004 | -3.0% | $0.135 | $0.14 | $0.125 | 1,638,286 | |
| $0.138 | -0.003 | -2.2% | $0.138 | $0.149 | $0.13 | 1,564,277 | |
| $0.141 | -0.012 | -7.8% | $0.153 | $0.154 | $0.138 | 1,632,890 | |
| $0.153 | -0.003 | -1.9% | $0.158 | $0.16 | $0.149 | 1,610,879 | |
| $0.156 | +0.003 | +2.0% | $0.156 | $0.179 | $0.15 | 7,729,847 | |
| $0.153 | +0.009 | +6.3% | $0.147 | $0.16 | $0.14 | 1,232,996 | |
| $0.144 | -0.027 | -15.6% | $0.177 | $0.177 | $0.12 | 2,234,675 | |
| $0.171 | -0.024 | -12.5% | $0.197 | $0.20 | $0.162 | 1,881,904 | |
| $0.195 | -0.015 | -7.1% | $0.216 | $0.22 | $0.185 | 2,088,722 | |
| $0.21 | -0.018 | -7.9% | $0.21 | $0.217 | $0.176 | 5,854,442 | |
| $0.228 | -0.257 | -53.0% | $0.333 | $0.353 | $0.212 | 36,573,659 | |
| $0.486 | -0.018 | -3.5% | $0.501 | $0.515 | $0.44 | 153,830 | |
| $0.503 | +0.021 | +4.2% | $0.52 | $0.52 | $0.461 | 128,460 | |
| $0.483 | -0.038 | -7.2% | $0.506 | $0.517 | $0.481 | 97,110 | |
| $0.52 | +0.021 | +4.2% | $0.50 | $0.523 | $0.49 | 85,290 | |
| $0.499 | +0.037 | +8.0% | $0.488 | $0.52 | $0.46 | 185,524 | |
| $0.462 | +0.012 | +2.6% | $0.455 | $0.50 | $0.431 | 313,041 | |
| $0.451 | -0.111 | -19.7% | $0.561 | $0.60 | $0.451 | 471,529 | |
| $0.561 | -0.019 | -3.3% | $0.56 | $0.61 | $0.56 | 27,198 | |
| $0.58 | -0.025 | -4.1% | $0.59 | $0.62 | $0.572 | 100,759 | |
| $0.605 | -0.003 | -0.4% | $0.595 | $0.64 | $0.58 | 69,240 | |
| $0.608 | +0.044 | +7.7% | $0.579 | $0.64 | $0.55 | 180,600 | |
| $0.564 | +0.023 | +4.3% | $0.534 | $0.59 | $0.53 | 297,596 | |
| $0.541 | +0.011 | +2.0% | $0.54 | $0.548 | $0.525 | 63,784 | |
| $0.53 | +0.018 | +3.4% | $0.525 | $0.54 | $0.50 | 233,163 | |
| $0.512 | -0.016 | -3.0% | $0.54 | $0.54 | $0.503 | 91,361 | |
| $0.528 | +0.017 | +3.4% | $0.529 | $0.55 | $0.485 | 279,804 | |
| $0.511 | -0.009 | -1.8% | $0.515 | $0.543 | $0.50 | 230,473 | |
| $0.52 | -0.002 | -0.3% | $0.54 | $0.55 | $0.515 | 120,250 | |
| $0.522 | -0.028 | -5.1% | $0.54 | $0.565 | $0.511 | 329,392 | |
| $0.55 | -0.04 | -6.8% | $0.581 | $0.606 | $0.55 | 570,644 | |
| $0.59 | -0.059 | -9.1% | $0.64 | $0.662 | $0.556 | 436,636 | |
| $0.649 | +0.015 | +2.4% | $0.63 | $0.68 | $0.62 | 351,107 | |
| $0.634 | +0.002 | +0.3% | $0.629 | $0.65 | $0.623 | 111,154 |
- Ticker
- NASDAQ:ADGM
- Asset type
- Stock
- Sector
- Health care
- Industry
- Medical devices & supplies
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 16, 2026
Adagio Medical Reports Third Quarter 2026 Results
Latest deck · Aug 13, 2026
Investor Presentation (August 2026)
Investor deck · 24 slides
Latest news
Adagio Medical Reports Third Quarter 2026 Results
Nov 16, 2026
Closed $1.61 (-16.6%) on Nov 16, 2026
Adagio Medical Provides Business Update: 22 Patients Treated with Next-Generation vCLAS™ Ultra System as FULCRUM-VT IDE Sub-Study Advances
Nov 10, 2026
Closed $1.84 (-4.2%) on Nov 10, 2026
Adagio Medical Announces Strategic Review Process to Maximize Shareholder Value
Sep 23, 2026
Closed $0.228 (-53.0%) on Sep 23, 2026
Adagio Medical Highlights First Patient Treated in IDE Study Evaluating Next-Generation vCLAS™ Ultra System for Ventricular Tachycardia at Banner – University Medical Center Phoenix
Sep 16, 2026
Closed $0.499 (+8.0%) on Sep 16, 2026
Adagio Medical Reports Second Quarter 2026 Results
Aug 11, 2026
Closed $0.719 (-3.4%) on Aug 11, 2026
Adagio Medical Treats First Patient with Faster, Single-Freeze Next-Generation ULTA System
Aug 3, 2026
Closed $0.46 (+21.6%) on Aug 3, 2026
Amendment to Annual Report (Form 10-K/A)
Jul 13, 2026
Closed $0.571 (+0.2%) on Jul 13, 2026
Adagio Medical Submits Premarket Approval Application to FDA for vCLAS® Ventricular Ablation System for the Treatment of Ventricular Tachycardia
May 21, 2026
Closed $0.845 (+0.1%) on May 21, 2026
Adagio Medical Reports First Quarter 2026 Results and Meaningful Clinical Progress
May 12, 2026
Closed $0.923 (-1.8%) on May 12, 2026
Adagio Medical to Participate in the BofA Securities 2026 Health Care Conference
Apr 29, 2026
Closed $1.05 (-3.7%) on Apr 29, 2026
Adagio Medical Holdings, Inc on 6ix
- Sector
- Health care
- Industry
- Medical devices & supplies
- News releases
- 27 in the last 12 months · 48 in all · newest Nov 16, 2026 · oldest 2024
- Decks
- 11 decks · latest Aug 13, 2026
Where Adagio Medical Holdings, Inc is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:ADGM · Home listing · This page | NASDAQ | United States | USD |
| BOATS:ADGM | BOATS | United States | USD |
Valuation
P/E 2.1× against a median of 7.6×: 2nd lowest of 3 Medical devices & supplies companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $636,010 USD
- P/E
- 2.1×
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.1×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.1×
- Beta vs S&P 500
- 0.69
Medical devices & supplies: the 10 companies nearest in size, of 448 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Adagio Medical Holdings, Inc · NASDAQ:ADGM | US$1.72M | US$636,010 | 2.1× | n/a | n/a | 0.1× | n/a | 0.1× | 0.69 |
| RemSleep Holdings, Inc. · OTC:RMSL | US$2.09M | US$2.06M | n/a | 123× | n/a | n/a | n/a | n/a | -0.01 |
| Fuse Medical, Inc. · OTC:FZMD | US$2.03M | US$4.31M | 14.8× | 0.5× | 7.8× | 0.3× | 1.5% | 0.4× | 0.54 |
| Nuwellis, Inc. · NASDAQ:NUWE | US$1.84M | −US$6.31M | n/a | −0.7× | n/a | 0.2× | −152.8% | 0.0× | 2.26 |
| Vivos Therapeutics, Inc. · NASDAQ:VVOS | US$1.83M | US$2.11M | n/a | 0.1× | n/a | 0.8× | −107.1% | 0.2× | 1.41 |
| Autonomix Medical, Inc. · NASDAQ:AMIX | US$1.82M | −US$5.87M | n/a | n/a | n/a | 0.3× | n/a | 0.0× | 1.79 |
| Escalon Medical Corp. · OTC:ESMC | US$1.71M | −US$1.96M | 0.4× | −0.1× | n/a | 0.3× | 32.8% | 0.0× | -0.06 |
| Therma Bright Inc. · TSXV:THRM | US$1.66M | US$1.64M | n/a | 17.3× | n/a | n/a | n/a | n/a | -0.15 |
| Nexalin Technology, Inc. · NASDAQ:NXL | US$1.45M | US$1.88M | n/a | 6.8× | n/a | 5.5× | n/a | 4.7× | 0.52 |
| Zero Candida Technologies Inc. · TSXV:ZCT | US$1.43M | −US$59,292 | n/a | n/a | n/a | 2.2× | n/a | 0.0× | -0.17 |
| Osteopore Ltd. · ASX:OSX | US$1.38M | US$596,079 | n/a | 0.3× | n/a | n/a | −121.8% | n/a | n/a |
| Median of the others | US$1.76M | US$1.12M | 7.6× | 0.4× | 7.8× | 0.3× | −107.1% | 0.0× | 0.52 |
Forecasts
2 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.
- Price target
- 105.00 USD · Analysts' mean
- EPS, year to Dec 2026
- -30.30 · 2 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Ilya Grigorov | Vice President |
| Deborah Kaster | Chief Business Officer |
Board
| Director | Role |
|---|---|
| Sean Salmon | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 16, 2026 · Before open | −16.6% |
| Q2 2026 | Aug 11, 2026 · Before open | −3.4% |
| Q1 2026 | May 12, 2026 · Before open | −1.8% |
| Q4 2025 | Mar 27, 2026 · Before open | −1.6% |
| Q3 2025 | Nov 12, 2025 | −6.5% |
| Q2 2025 | Aug 14, 2025 | +0.8% |
| Q1 2025 | May 15, 2025 | −3.3% |
| Q4 2024 | Mar 27, 2025 | +0.5% |
| Q1 2023 | Apr 6, 2023 | −0.1% |
| Q3 2022 | Nov 7, 2022 | 0.0% |
All 16 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q2 2022 | Aug 8, 2022 | −0.2% |
| Q1 2022 | May 13, 2022 | −0.4% |
| Q4 2021 | Mar 31, 2022 | −0.4% |
| Quarter to Sep 30, 2021 | Nov 12, 2021 | 0.0% |
| Quarter to Jun 30, 2021 | Aug 12, 2021 | +0.2% |
| Quarter to Mar 31, 2021 | May 13, 2021 | −3.0% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (August 2026) | Investor deck | 24 slides | Aug 13, 2026 |
| BofA Securities 2026 Health Care Conference | Conference | 25 slides | May 2026 |
| Technical Presentation (April 2026) | Technical | 20 slides | Apr 27, 2026 |
| Investor Presentation (February 2026) | Investor deck | 25 slides | February 2026 |
| Technical Presentation (October 2025) | Technical | 15 slides | Oct 10, 2025 |
| Investor Presentation (August 2025) | Investor deck | 20 slides | August 2025 |
| B of A Securities Health Care Conference 2025 | Conference | 16 slides | May 13, 2025 |
| TD Cowen 45th Annual Healthcare Conference 2025 | Conference | 24 slides | Mar 4, 2025 |
| SPAC Merger (June 2024) | SPAC merger | 94 slides | Jun 11, 2024 |
| SPAC Merger (April 2024) | SPAC merger | 95 slides | Apr 24, 2024 |
All 11 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| SPAC Merger (February 2024) | SPAC merger | 77 slides | Feb 14, 2024 |
Financings
| Raise | Date |
|---|---|
| Private placement of shares of common stock (or pre-funded warrants) and accompanying common warrants Announced: about US$19M · US$1.9403 a share · Warrants at US$1.71 for 60 months · Piper Sandler +1 Dealers: Piper Sandler (lead), Lake Street Buyers: Perceptive Advisors, LLC (affiliate) Use of proceeds: Working capital and general corporate purposes, including clinical and product development activities | Oct 15, 2025 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 269.0K | 300.0K | 189.0K | 270.0K | |
| Cost of revenue | 684.0K | 1.94M | 1.31M | 875.0K | 1.16M | |
| Gross profit | -684.0K | -1.67M | -1.01M | -686.0K | -888.0K | |
| Research and development | 10.6M | 4.63M | 15.4M | 17.9M | 15.4M | |
| Selling, general and administrative | 10.6M | 11.5M | 1.01M | 6.61M | ||
| Operating income | -21.9M | -62.5M | -27.9M | -23.9M | -20.6M | -13.5K |
| Depreciation and amortization | 970.0K | 1.39M | 532.0K | 495.0K | 336.0K | |
| EBITDA | -20.9M | -61.1M | -27.4M | -23.4M | -20.3M | |
| Interest expense | 2.91M | 1.10M | 1.66M | 137.0K | 0 | |
| Income before tax | -25.3M | -53.8M | -36.6M | -23.7M | -19.9M | -13.5K |
| Income tax | 0 | 0 | 0 | |||
| Net income | -25.1M | -53.8M | -36.6M | -23.7M | -19.9M | -13.5K |
| Earnings per share, basic | -1.51 | -3.54 | -48.16 | -37.02 | -1.04 | -0.00 |
| Earnings per share, diluted | -1.51 | -48.16 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | 17.1M | 20.6M | 1.38M | 5.55M | 18.9M | |
| Short-term investments | 1.36M | |||||
| Receivables | 0 | 35.0K | 71.0K | -6.59M | 33.0K | |
| Inventory | 1.67M | 2.57M | 3.32M | 367.0K | 334.0K | |
| Current assets | 20.1M | 25.3M | 5.18M | 6.73M | 19.7M | 1.75K |
| Property, plant and equipment | 1.53M | 1.96M | 1.49M | |||
| Goodwill | 14.0M | 14.0M | 0 | |||
| Total assets | 43.3M | 48.4M | 6.83M | 8.70M | 21.4M | 42.5K |
| Accounts payable | 1.08M | 2.84M | 3.83M | 1.01M | 578.0K | 25.0K |
| Current liabilities | 8.23M | 7.76M | 47.2M | 13.0M | 2.59M | 56.0K |
| Long-term debt | 21.0M | 16.1M | 143.0K | |||
| Total debt | 21.0M | 17.2M | 38.3M | 9.80M | 11.2K | |
| Total liabilities | 30.9M | 28.5M | 47.4M | 104.6M | 94.1M | 56.0K |
| Shareholders' equity | 12.4M | 19.9M | -132.0M | -95.9M | -72.6M | -13.5K |
| Shares outstanding | 740.3K | 15.2M | 779.9K | 639.5K | 19.2M | 19.2M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cash from operations | -19.0M | -29.5M | -25.7M | -22.4M | -19.3M |
| Capital spending | -374.0K | -1.65M | -333.0K | -492.0K | -1.27M |
| Free cash flow | -19.4M | -31.1M | -26.0M | -22.9M | -20.6M |
| Cash from investing | -374.0K | -1.65M | -340.0K | -500.0K | -1.27M |
| Cash from financing | 16.1M | 15.6M | 21.9M | 9.53M | 130.0K |
| Share buybacks | -115.1M | ||||
| Change in cash | -3.48M | 20.6M | -4.16M | 5.05M | -20.4M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| DEF 14A · Proxy statement | Nov 20, 2026 | Meeting notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 16, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 16, 2026 | Results | SEC |
| PRE 14A · Preliminary proxy statement | Nov 10, 2026 | Meeting notice | SEC |
| 8-K · Current report | Nov 5, 2026 | Current report | SEC |
| 8-K · Current report | Oct 26, 2026 | Meeting outcome | SEC |
| 4 · Change in ownership | Oct 13, 2026 | Insider trade | SEC |
| DEF 14A · Proxy statement | Oct 13, 2026 | Meeting notice | SEC |
| 8-K · Current report | Oct 1, 2026 | Financing | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| PRE 14A · Preliminary proxy statement | Oct 1, 2026 | Meeting notice | SEC |
| 8-K · Current report | Sep 23, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Aug 14, 2026 | Current report | SEC |
| 8-K · Current report | Aug 13, 2026 | Current report | SEC |
| 4 · Change in ownership | Aug 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 12, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 11, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 11, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 28, 2026 | Big-stake notice | SEC |
| 10-K/A · Annual report, amended | Jul 13, 2026 | Annual report | SEC |
| 8-K · Current report | Jun 16, 2026 | Meeting outcome | SEC |
| 8-K · Current report | Jun 12, 2026 | Current report | SEC |
| 8-K · Current report | May 21, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 13, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 12, 2026 | Results | SEC |
| ARS · Annual report to shareholders | Apr 30, 2026 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 30, 2026 | Meeting notice | SEC |
| 8-K · Current report | Apr 27, 2026 | Current report | SEC |
| 8-K · Current report | Apr 20, 2026 | Current report | SEC |
| 8-K · Current report | Apr 8, 2026 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Apr 6, 2026 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Apr 6, 2026 | Other filings | SEC |
| S-8 POS | Apr 2, 2026 | Offer document | SEC |
| POS AM · Amendment to an effective registration | Apr 2, 2026 | Offer document | SEC |
| POS AM · Amendment to an effective registration | Apr 2, 2026 | Offer document | SEC |
| POS AM · Amendment to an effective registration | Mar 31, 2026 | Offer document | SEC |
| POS AM · Amendment to an effective registration | Mar 31, 2026 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Mar 27, 2026 | Offer document | SEC |
| 424B3 · Prospectus | Mar 27, 2026 | Offer document | SEC |
| 424B3 · Prospectus | Mar 27, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 27, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 27, 2026 | Results | SEC |
| 4 · Change in ownership | Mar 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 9, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 11, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Dec 18, 2025 | Insider trade | SEC |
| 424B3 · Prospectus | Dec 16, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Dec 16, 2025 | Offer document | SEC |
| 8-K · Current report | Dec 16, 2025 | Meeting outcome | SEC |
| 4 · Change in ownership | Dec 15, 2025 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Dec 15, 2025 | Other filings | SEC |
| 424B3 · Prospectus | Dec 12, 2025 | Offer document | SEC |
| 4 · Change in ownership | Dec 11, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Dec 11, 2025 | Insider trade | SEC |
| 424B3 · Prospectus | Dec 11, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Dec 11, 2025 | Offer document | SEC |
| DEFA14A · Additional proxy material | Dec 11, 2025 | Meeting notice | SEC |
| 8-K · Current report | Dec 11, 2025 | Management or board change | SEC |
| CORRESP · Letter to the SEC | Dec 10, 2025 | Other filings | SEC |
| S-3 · Registration statement | Nov 21, 2025 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 13, 2025 | Big-stake notice | SEC |
| 424B3 · Prospectus | Nov 12, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Nov 12, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2025 | Results | SEC |
| ARS · Annual report to shareholders | Nov 4, 2025 | Annual report | SEC |
| DEF 14A · Proxy statement | Nov 4, 2025 | Meeting notice | SEC |
| D | Oct 29, 2025 | Other filings | SEC |
| 424B3 · Prospectus | Oct 24, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Oct 24, 2025 | Offer document | SEC |
| 8-K · Current report | Oct 24, 2025 | Current report | SEC |
| 4 · Change in ownership | Oct 22, 2025 | Insider trade | SEC |
| 424B3 · Prospectus | Oct 20, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Oct 20, 2025 | Offer document | SEC |
| 8-K · Current report | Oct 20, 2025 | Current report | SEC |
| 424B3 · Prospectus | Oct 15, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Oct 15, 2025 | Offer document | SEC |
| 8-K · Current report | Oct 15, 2025 | Material contract | SEC |
| 424B3 · Prospectus | Oct 10, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Oct 10, 2025 | Offer document | SEC |
| 8-K · Current report | Oct 10, 2025 | Current report | SEC |
| 424B3 · Prospectus | Oct 1, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Oct 1, 2025 | Offer document | SEC |
| 8-K · Current report | Oct 1, 2025 | Current report | SEC |
| 3 · Initial statement of ownership | Sep 30, 2025 | Insider trade | SEC |
| 424B3 · Prospectus | Sep 8, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Sep 8, 2025 | Offer document | SEC |
| 8-K · Current report | Sep 8, 2025 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 26, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| 424B3 · Prospectus | Aug 13, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Aug 13, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 13, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 13, 2025 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 12, 2025 | Big-stake notice | SEC |
| 424B3 · Prospectus | May 15, 2025 | Offer document | SEC |
| 424B3 · Prospectus | May 15, 2025 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 15, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 15, 2025 | Results | SEC |
| 424B3 · Prospectus | May 1, 2025 | Offer document | SEC |
| 424B3 · Prospectus | May 1, 2025 | Offer document | SEC |
| 10-K/A · Annual report, amended | Apr 30, 2025 | Annual report | SEC |
| 3 · Initial statement of ownership | Apr 28, 2025 | Insider trade | SEC |
| 424B3 · Prospectus | Apr 23, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Apr 23, 2025 | Offer document | SEC |
| 8-K · Current report | Apr 23, 2025 | Management or board change | SEC |
| 8-K · Current report | Apr 2, 2025 | Results | SEC |
| S-8 · Registration statement for employee plans | Mar 27, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Mar 27, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Mar 27, 2025 | Offer document | SEC |
| 10-K · Annual report | Mar 27, 2025 | Annual report | SEC |
| 4 · Change in ownership | Mar 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 21, 2025 | Insider trade | SEC |
| 424B3 · Prospectus | Mar 17, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Mar 17, 2025 | Offer document | SEC |
| 8-K · Current report | Mar 17, 2025 | Management or board change | SEC |
| 424B3 · Prospectus | Mar 4, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Mar 4, 2025 | Offer document | SEC |
| 8-K · Current report | Mar 4, 2025 | Management or board change | SEC |
| 424B3 · Prospectus | Feb 28, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Feb 28, 2025 | Offer document | SEC |
| 8-K · Current report | Feb 28, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 14, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 13, 2025 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Feb 10, 2025 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Feb 10, 2025 | Other filings | SEC |
| 424B3 · Prospectus | Feb 7, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Feb 7, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Feb 5, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Feb 5, 2025 | Offer document | SEC |
| 8-K · Current report | Feb 5, 2025 | Current report | SEC |
| CORRESP · Letter to the SEC | Feb 5, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Feb 5, 2025 | Other filings | SEC |
| S-1/A · Registration statement, amended | Feb 4, 2025 | Offer document | SEC |
| S-1/A · Registration statement, amended | Feb 4, 2025 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Jan 22, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jan 22, 2025 | Other filings | SEC |
| S-1 · Registration statement | Jan 14, 2025 | Offer document | SEC |
| S-1 · Registration statement | Jan 14, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Jan 6, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Jan 6, 2025 | Offer document | SEC |
| 8-K · Current report | Jan 6, 2025 | Material contract | SEC |
| 424B3 · Prospectus | Dec 23, 2024 | Offer document | SEC |
| 424B3 · Prospectus | Dec 23, 2024 | Offer document | SEC |
| 8-K · Current report | Dec 23, 2024 | Management or board change | SEC |
| 3 · Initial statement of ownership | Dec 20, 2024 | Insider trade | SEC |
| 424B3 · Prospectus | Dec 16, 2024 | Offer document | SEC |
| 424B3 · Prospectus | Dec 16, 2024 | Offer document | SEC |
| 8-K · Current report | Dec 16, 2024 | Material contract | SEC |
| 424B3 · Prospectus | Nov 26, 2024 | Offer document | SEC |
| 424B3 · Prospectus | Nov 26, 2024 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Nov 26, 2024 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Nov 26, 2024 | Other filings | SEC |
| POS AM · Amendment to an effective registration | Nov 25, 2024 | Offer document | SEC |
| POS AM · Amendment to an effective registration | Nov 22, 2024 | Offer document | SEC |
| 424B3 · Prospectus | Nov 14, 2024 | Offer document | SEC |
| 424B3 · Prospectus | Nov 14, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 14, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 14, 2024 | Results | SEC |
| SC 13G · Big-stake notice | Nov 13, 2024 | Big-stake notice | SEC |
| POS AM · Amendment to an effective registration | Nov 8, 2024 | Offer document | SEC |
| POS AM · Amendment to an effective registration | Nov 8, 2024 | Offer document | SEC |
| 8-K/A · Current report, amended | Nov 4, 2024 | Current report | SEC |
| 8-K · Current report | Nov 1, 2024 | Current report | SEC |
| S-8 · Registration statement for employee plans | Oct 8, 2024 | Offer document | SEC |
| 4 · Change in ownership | Oct 1, 2024 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Sep 20, 2024 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Sep 20, 2024 | Other filings | SEC |
| 424B3 · Prospectus | Sep 19, 2024 | Offer document | SEC |
| 424B3 · Prospectus | Sep 19, 2024 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Sep 17, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Sep 17, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 17, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 17, 2024 | Other filings | SEC |
| S-1 · Registration statement | Sep 13, 2024 | Offer document | SEC |
| S-1 · Registration statement | Sep 13, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 26, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 19, 2024 | Current report | SEC |
| 8-K/A · Current report, amended | Aug 14, 2024 | Acquisition or disposal | SEC |
| SC 13G · Big-stake notice | Aug 12, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Aug 6, 2024 | Acquisition or disposal | SEC |
| 4 · Change in ownership | Aug 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 2, 2024 | Insider trade | SEC |
This page holds 200 of 239 filings. Open Filings
Cap table
Built by 6ix from Adagio Medical Holdings, Inc’s releases · as of Nov 11, 2026
- Common shares
- 983,434
- Fully diluted
- 983,434
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 983,434 | Nov 11, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 11, 2026 | 983,434 |
| Nov 9, 2026 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Joseph Edelman Other companies: Kardigan, Inc. (Director · Since at least Jun 17, 2026); Immatics N.V. (Director · Since at least Mar 18, 2026); Solid Biosciences Inc. (Director · Since at least Mar 23, 2021); MeiraGTx Holdings plc (Director · Since at least Nov 23, 2020); LeonaBio, Inc. (Director · Since at least Sep 17, 2020); Freenome, Inc. (Director · Jun 11, 2024 – Jun 11, 2024 · Past); ARYA Sciences Acquisition Corp V (Director · Jul 12, 2021 – Jul 12, 2021 · Past); ARYA Sciences Acquisition IV Corp (Director · Feb 25, 2021 – Jul 31, 2024 · Past); Landos Biopharma Inc (Director · Feb 3, 2021 – Aug 27, 2021 · Past); Astria Therapeutics Inc (Director · Jan 28, 2021 – Feb 1, 2024 · Past); Nautilus Biotechnology, Inc. (Director · Aug 6, 2020 – Jun 14, 2024 · Past); Cerevel Therapeutics Holdings Inc (Director · Jun 4, 2020 – Feb 20, 2024 · Past); Lyra Therapeutics, Inc. (Director · Apr 30, 2020 – May 31, 2023 · Past); ARYA Sciences Acquisition Corp (Director · Oct 5, 2018 – Oct 5, 2018 · Past) | Director · Jan 22, 2025 – Jan 22, 2025 · Past |
| Sandra A Gardiner Other companies: Kronos Bio Inc (Interim CFO · Sep 15, 2023 – Sep 15, 2023 · Past); Nektar Therapeutics (Chief Financial Officer · Apr 17, 2023 – Apr 17, 2023 · Past); Anebulo Pharmaceuticals, Inc. (Acting Chief Financial Officer · Mar 2, 2023 – Mar 2, 2023 · Past); Lucira Health Inc (Director · Feb 4, 2021 – Jun 1, 2022 · Past); Pulse Biosciences, Inc (CFO & EVP Admin. and Finance · Dec 9, 2020 – Dec 14, 2021 · Past) | Director · Since at least Jul 31, 2024 |
| Olav Bergheim Other companies: Sonendo, Inc. (Director · Since at least Oct 28, 2021); Glaukos Corporation (Director · Jun 24, 2015 – Jul 23, 2015 · Past); Volcano Corp (Director · Jun 14, 2006 – Aug 1, 2008 · Past) | CEO and Chairman, Director · Jul 31, 2024 – Jul 31, 2024 · Past |
| Daniel George Other companies: Anebulo Pharmaceuticals, Inc. (Acting Chief Financial Officer · Since at least Sep 28, 2023); Lucira Health Inc (CFO and Treasurer · Feb 4, 2021 – Sep 18, 2022 · Past) | Interim CFO · Apr 17, 2025 – Apr 17, 2025 · Past |
| James L. Cox Other companies: Lucid Diagnostics Inc. (Director · Since at least Oct 13, 2021); PAVmed Inc. (Director · Apr 1, 2021 – Feb 22, 2024 · Past) | Director · Since at least Jul 31, 2024 |
| John T Dahldorf Other companies: Hyperfine, Inc. (Director · Since at least Dec 22, 2021); Volcano Corp (CFO · Jun 14, 2006 – Feb 17, 2015 · Past) | Chief Financial Officer · Jul 31, 2024 – Jul 31, 2024 · Past |
| Sean Salmon Other companies: Teleflex Incorporated (Executive · Since at least Sep 8, 2026); Medtronic plc. (EVP & President Cardiovascular · Nov 1, 2019 – Dec 16, 2024 · Past) | Director · Since at least Dec 11, 2025 |
| Timothy Moran Other companies: Kestra Medical Technologies, Ltd. (Chief Business Officer · Since at least Oct 7, 2025); Motus GI Holdings, Inc. (Director · Nov 11, 2020 – Mar 5, 2024 · Past) | Director · Since at least Jul 31, 2024 |
| Orly Mishan Other companies: Cerevel Therapeutics Holdings Inc (Chief Business Officer · Oct 27, 2020 – Jan 25, 2021 · Past) | Director · Since at least Jul 31, 2024 |
| Todd Usen Other companies: Minerva Surgical, Inc. (Chief Executive Officer, Director · Jan 2, 2023 – Jan 2, 2023 · Past) | Chairperson of the Board · Since at least Dec 13, 2024 |
All 15 people
| Person | Seat |
|---|---|
| Deborah Kaster | Chief Business Officer · Since at least Mar 31, 2025 |
| Hakon Bergheim | Chief Operating Officer · Jul 31, 2024 – Jul 31, 2024 · Past |
| Ilya Grigorov | Vice President · Since at least Mar 31, 2025 |
| Keyvan Mirsaeedi-Farahani | Director · Since at least Jul 31, 2024 |
| Shahram Moaddeb | Director · Jul 31, 2024 – Jul 31, 2024 · Past |
Log in to ask 6ix AI your own questions about Adagio Medical Holdings, Inc.